Key clinical point: Hepatic arterial infusion chemotherapy is a safe and effective treatment option for patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis (PVTT).
Major finding: Overall survival rates were 29.2 months, 4.55 months, and 11.52 months for HCC patients with PVTT who were treated with hepatic arterial infusion chemotherapy, best supportive care, and sorafenib, respectively.
Study details: The data come from a case-control study of 91 adults with advanced HCC and portal vein tumor thrombosis; 20 were treated with hepatic arterial infusion chemotherapy (HAIC), while 42 received best supportive care, and 29 received sorafenib.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Abdelmaksoud AHK et al. Clin Radiol. 2021 Jun 8. doi: 10.1016/j.crad.2021.03.022.